文献速递角膜与眼表疾病

粪菌移植治疗免疫介导性干眼的安全性研究

Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye.
PubMed 文献 · Am J Ophthalmol · 2021-06-30

这项开放标签非随机临床试验评估了粪菌移植(FMT)在10例免疫介导性干眼(符合干燥综合征或早期标志物阳性)患者中的安全性,受试者接受2次健康供体FMT灌肠、间隔1周。结果显示无不良事件,8例肠道菌群向供体靠近,5例在3个月时主观报告干眼症状改善。

要点

  • FMT在免疫介导性干眼患者中安全,未观察到不良事件。
  • FMT后8例肠道菌群向供体靠近,部分菌群持续至3个月。
  • 5例受试者3个月时主观报告干眼症状改善。

核心结论

  • FMT在免疫介导性干眼患者中安全实施,部分细菌谱在3个月时仍接近供体。
  • 一半受试者报告干眼症状改善,最有效的FMT给药方式尚未确定。

研究设计与样本

  • 开放标签、非随机临床试验,纳入10例有干眼症状和体征且符合干燥综合征或早期干燥综合征标志物阳性的个体。
  • 干预为来自单一健康供体的2次FMT,经灌肠给药,间隔1周;主要结局为安全性。

主要发现

  • 人群平均年龄60.4岁,30%为男性,50%为白人,50%为西班牙裔。
  • 基线时所有受试者肠道菌群谱与供体显著不同,包括更高的平均多样性指数。
  • 受试者Faecalibacterium、Prevotella和Ruminococcus属丰度降低,Alistipes、Streptococcus和Blautia属丰度增加(与供体相比)。
  • FMT后8例受试者肠道菌群谱向供体靠近;所有随访时间点作为一组,菌群谱更接近原始受试者而非供体,但某些门、纲和属的OTU数量至3个月时仍更接近供体而非受试者基线。

临床怎么用

  • 对于免疫介导性干眼患者,FMT可能是一种安全且有望改善症状的干预,但需进一步研究确定最佳给药方式。
  • 临床可关注肠道菌群与干眼症状及T细胞谱的关联,但FMT尚未成为标准治疗。

局限性

  • 开放标签、非随机设计,样本量小(10例),无对照组。
  • 主要结局为安全性,疗效为次要观察,主观症状改善需更大样本验证。
  • 最有效的FMT给药方式尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety of the Fecal Microbial Transplant for Sjogren Syndrome (FMT) trial in individuals with immune-mediated dry eye (DE). DESIGN: Open-label, nonrandomized clinical trial. METHODS: The study population included 10 individuals with DE symptoms and signs meeting criteria for Sjögren or positive early Sjögren markers. Procedures were 2 FMTs from a single healthy donor delivered via enema, 1 week apart. The primary outcome measure was safety. In addition, gut microbiome profiles, DE metrics, and T-cell profiles in blood were examined at baseline before FMT, and at 1 week, 1 month, and 3 months after FMT. RESULTS: The mean age of the population was 60.4 years; 30% were male; 50% were white; and 50% were Hispanic. At baseline, all subjects had significantly different gut microbiome profiles from the donor, including higher mean diversity indices. Subjects had a decreased abundance of genera Faecalibacterium, Prevotella, and Ruminococcus and an increased abundance of genera Alistipes, Streptococcus, and Blautia compared to the donor. Effector and regulatory T-cell profiles were positively correlated with each other and with DE symptom severity (T helper 1 cells [Th1]; r = .76; P = .01; Th17: r = 0.83; P = .003; CD25: r = 0.66; P = .04; FoxP3: r = 0.68; P = .03). No adverse events were noted with FMT. After FMT, gut microbiome profiles in 8 subjects moved closer to the donor's profile. As a group, gut microbiome profiles at all follow-up time points were more similar to the original recipients' than the donor's microbiome; however, certain phyla, classes, and genera operational taxonomic unit (OTU) numbers remained closer to the donor vs recipients' baseline profiles out to 3 months. Five individuals subjectively reported improved dry eye symptoms 3 months after FMT. CONCLUSIONS: FMT was safely performed in individuals with immune-mediated DE, with certain bacterial profiles resembling the donor out to 3 months after FMT. One-half the subjects reported improved DE symptoms. The most effective FMT administration method has yet to be determined.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Watane A, Cavuoto KM, Rojas M, et al. Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye. Am J Ophthalmol. 2021. PMID: 34214453. doi:10.1016/j.ajo.2021.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。